僧帽弁逆流の重症度を評価するためのフェニレフリンの使用
経食道心エコー検査中にフェニレフリンを使用して僧帽弁逆流の重症度を評価する
The study proposes to develop a phenylephrine protocol to be used during transesophageal echocardiography (TEE), whereby intravenous phenylephrine would be used to increase afterload with the intent to mimic the awake hemodynamic profile and variation that occurs with normal physical activity. The expectation is to see changes in severity of Mitral Regurgitation (MR) grade with increasing afterload, which in turn can provide more accurate quantification of MR severity to assist in clinical decision making.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Routine echocardiography which is used to assess the severity of mitral regurgitation, sometimes underestimates the severity of mitral regurgitation, due to hemodynamic variations that occurs with normal physical activity and under the effect of sedation which is used to perform transesophageal echocardiography. By using phenylephrine during transesophageal echocardiography, the study intends to offset the hemodynamic variation that occurs with sedation and better assess the severity of mitral regurgitation, which would further assist in clinical decision-making regarding treatment. The goal of this study is to compare the severity of mitral regurgitation grade before and after the administration of phenylephrine during transesophageal echocardiography and to demonstrate a 25% increase in severity of mitral regurgitation grade compared to the baseline conditions, following the administration of phenylephrine.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10470
- Montefiore Medical Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients 18 years or older with MR on baseline echocardiographic evaluation who are scheduled to undergo TEE for further evaluation of mitral regurgitation.
Exclusion Criteria:
-
The following patients will be excluded from the study:
- Patients who are not clinically eligible for TEE.
- Patients with contraindications to esophageal intubation.
- Patients with hemodynamic instability.
- Patients with acute decompensated heart failure (HF).
- Patients with un-revascularized severe coronary artery disease (triple vessel or left main disease).
- Patients with ongoing unstable angina or ongoing myocardial infarction (MI)
- Patients with significant arrhythmias including atrial fibrillation.
- Patients with uncontrolled hypertension (BP ≥ 150/90 mmHg).
- Patients with preexisting bradycardia (HR < 50) and heart blocks.
- Patients with severe symptomatic peripheral vascular disease.
- Patients with severe pulmonary hypertension (estimated systolic pulmonary arterial pressure sPAP ≥ 60mm Hg).
- Patients who are at high risk for intracranial bleeding such as patients with previous strokes, transient ischemic attack (TIA) and vascular malformations.
- Additionally, patients with mean arterial blood pressure MAP > 100 mmHg during TEE and those with severe MR, effective regurgitant orifice area (ERO > 39cm2) on baseline TEE evaluation will not be given phenylephrine and excluded from the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Phenylephrine Hydrochloride
Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection. A 20 mcg intravenous test dose of phenylephrine will be administered by the cardiologist performing the TEE. BP will be monitored after each bolus of phenylephrine. Subsequent phenylephrine injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed. |
Phenylephrine hydrochloride injection (10 mg/mL) was diluted to 100 mcg/mL (10 mg in 99 mL of 5% dextrose or 0.9% sodium chloride) for intravenous bolus administration. A 20 mcg test dose was administered by the cardiologist performing the TEE, followed by 50 mcg boluses every 10-15 minutes until mean arterial pressure (MAP) increased by ≥20 mmHg from baseline MAP, without exceeding a MAP of 100 mmHg. Blood pressure was monitored after each bolus. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. RVol is a measure of volume overload and represents the total volume of blood leaking backward into the left atria each beat. RVol will be quantitatively graded by the Proximal Isovelocity Surface Area (PISA) method on TEE, before and after phenylephrine administration. Participants were counted if post-phenylephrine RVol increased by greater than 25% from pre-phenylephrine RVol. |
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
|
Change in Effective Regurgitant Orifice Area (ERO)
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. ERO reflects the size of the regurgitant lesion and measures lesion severity. ERO is measured on TEE and graded using the PISA method (regurgitant flow = 2 × π × r² × aliasing velocity), before and after phenylephrine administration. Change is calculated as post-phenylephrine ERO minus pre-phenylephrine ERO and reported in square centimeters (cm²). Positive values indicate an increase in ERO area. |
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
|
Change in 3D Vena Contracta Diameter
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Change in vena contracta diameter, assessed before and after phenylephrine, will be measured in millimeters (mm) by 3D TEE. Change is calculated as post-phenylephrine value minus pre-phenylephrine value and reported in millimeters (mm). Positive values indicate an increase in vena contracta diameter. |
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
|
Change in Visual Mitral Regurgitation Grade
時間枠:Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Semi-quantitative visual MR is assessed during TEE before and after phenylephrine and graded on a 4-point scale ranging from 1 ("mild") to 4 ("severe"), integrating PISA-derived ERO/RVol and 3D vena contracta. Change calculated as post-phenylephrine grade minus pre-phenylephrine grade. Positive values indicate worsening MR grade. |
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Mario Garcia, MD、Montefiore Medical Center
出版物と役立つリンク
一般刊行物
- Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. 2008 Jul 29;52(5):319-26. doi: 10.1016/j.jacc.2008.02.084.
- Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Jul 11;70(2):252-289. doi: 10.1016/j.jacc.2017.03.011. Epub 2017 Mar 15. No abstract available.
- Shiran A, Merdler A, Ismir E, Ammar R, Zlotnick AY, Aravot D, Lazarovici H, Zisman E, Pizov R, Lewis BS. Intraoperative transesophageal echocardiography using a quantitative dynamic loading test for the evaluation of ischemic mitral regurgitation. J Am Soc Echocardiogr. 2007 Jun;20(6):690-7. doi: 10.1016/j.echo.2006.11.004.
- Sanfilippo F, Johnson C, Bellavia D, Morsolini M, Romano G, Santonocito C, Centineo L, Pastore F, Pilato M, Arcadipane A. Mitral Regurgitation Grading in the Operating Room: A Systematic Review and Meta-analysis Comparing Preoperative and Intraoperative Assessments During Cardiac Surgery. J Cardiothorac Vasc Anesth. 2017 Oct;31(5):1681-1691. doi: 10.1053/j.jvca.2017.02.046. Epub 2017 Feb 13.
- Kolev N, Brase R, Wolner E, Zimpfer M. Quantification of mitral regurgitant flow using proximal isovelocity surface area method: a transesophageal echocardiography perioperative study. J Cardiothorac Vasc Anesth. 1998 Feb;12(1):22-6. doi: 10.1016/s1053-0770(98)90050-7.
- Recusani F, Bargiggia GS, Yoganathan AP, Raisaro A, Valdes-Cruz LM, Sung HW, Bertucci C, Gallati M, Moises VA, Simpson IA, et al. A new method for quantification of regurgitant flow rate using color Doppler flow imaging of the flow convergence region proximal to a discrete orifice. An in vitro study. Circulation. 1991 Feb;83(2):594-604. doi: 10.1161/01.cir.83.2.594.
- Lehmann KG, Francis CK, Dodge HT. Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group. Ann Intern Med. 1992 Jul 1;117(1):10-7. doi: 10.7326/0003-4819-117-1-10.
- Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999 Mar 15;83(6):897-902. doi: 10.1016/s0002-9149(98)01064-9.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- 2020-11414
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。